CN112543755A - 一类细胞坏死抑制剂及其制备方法和用途 - Google Patents

一类细胞坏死抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN112543755A
CN112543755A CN201980052128.3A CN201980052128A CN112543755A CN 112543755 A CN112543755 A CN 112543755A CN 201980052128 A CN201980052128 A CN 201980052128A CN 112543755 A CN112543755 A CN 112543755A
Authority
CN
China
Prior art keywords
substituted
compound
unsubstituted
nmr
cdcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980052128.3A
Other languages
English (en)
Inventor
马大为
季玉华
何卫明
方超
赵金龙
王开亮
夏尚华
李征
李盈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810676651.0A external-priority patent/CN110642874B/zh
Application filed by Shanghai Institute of Organic Chemistry of CAS filed Critical Shanghai Institute of Organic Chemistry of CAS
Publication of CN112543755A publication Critical patent/CN112543755A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

本申请提供了一类细胞坏死抑制剂及其制备方法和用途，具体地，本申请提供了一种抑制细胞坏死和/或人受体相互作用蛋白1激酶(RIP1)的抑制剂，所述的抑制剂具有如下式I所示的结构。所述化合物及包含其的组合物可用于预防和/或治疗涉及细胞死亡和/或炎症的疾病。(I)

Description

PCT国内申请，说明书已公开。

Claims (28)

  1. PCT国内申请，权利要求书已公开。
CN201980052128.3A 2018-06-26 2019-06-25 一类细胞坏死抑制剂及其制备方法和用途 Pending CN112543755A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810676651.0A CN110642874B (zh) 2018-06-26 2018-06-26 一类细胞坏死抑制剂及其制备方法和用途
CN2018106766510 2018-06-26
CN201910517015 2019-06-14
CN2019105170158 2019-06-14
PCT/CN2019/092705 WO2020001420A1 (zh) 2018-06-26 2019-06-25 一类细胞坏死抑制剂及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN112543755A true CN112543755A (zh) 2021-03-23

Family

ID=68986065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980052128.3A Pending CN112543755A (zh) 2018-06-26 2019-06-25 一类细胞坏死抑制剂及其制备方法和用途

Country Status (10)

Country Link
US (1) US20210292340A1 (zh)
EP (1) EP3816163A4 (zh)
JP (1) JP2022511213A (zh)
KR (1) KR20210024574A (zh)
CN (1) CN112543755A (zh)
AU (1) AU2019296091A1 (zh)
CA (1) CA3104757A1 (zh)
IL (1) IL279637A (zh)
TW (1) TW202019913A (zh)
WO (1) WO2020001420A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115806557A (zh) * 2021-09-14 2023-03-17 中国科学院上海有机化学研究所 抑制细胞程序性死亡的化合物及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384510A (zh) 2018-05-03 2021-02-19 里格尔药品股份有限公司 Rip1抑制性化合物以及制备和使用其的方法
PL3788044T3 (pl) 2018-05-03 2024-02-12 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
EP4025572A1 (en) 2019-09-06 2022-07-13 Rigel Pharmaceuticals, Inc. Heterocyclic rip1 kinase inhibitors
CN115298184A (zh) 2019-11-07 2022-11-04 里格尔药品股份有限公司 杂环rip1抑制化合物
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
CN115038707A (zh) * 2020-05-14 2022-09-09 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途
AR122703A1 (es) 2020-07-01 2022-09-28 Rigel Pharmaceuticals Inc Inhibidores de rip1k
WO2022171110A1 (en) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Fused tricyclic compounds as rip1-kinase inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121432A (zh) * 2013-02-15 2015-12-02 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的杂环酰胺
WO2017109724A1 (en) * 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN109134448A (zh) * 2018-10-16 2019-01-04 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物
CN110642874A (zh) * 2018-06-26 2020-01-03 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170042595A (ko) * 2014-08-21 2017-04-19 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 의약으로서의 rip1 키나제 억제제로서의 헤테로시클릭 아미드
US10702527B2 (en) * 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2988601C (en) * 2015-07-02 2021-12-07 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
EP3366684B1 (en) * 2015-10-23 2020-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
SG10201913587WA (en) * 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
CN109843886B (zh) * 2016-10-17 2022-04-19 豪夫迈·罗氏有限公司 二环吡啶酮内酰胺及其使用方法
US11072607B2 (en) * 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121432A (zh) * 2013-02-15 2015-12-02 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的杂环酰胺
WO2017109724A1 (en) * 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN110642874A (zh) * 2018-06-26 2020-01-03 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
CN109134448A (zh) * 2018-10-16 2019-01-04 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115806557A (zh) * 2021-09-14 2023-03-17 中国科学院上海有机化学研究所 抑制细胞程序性死亡的化合物及其制备方法

Also Published As

Publication number Publication date
TW202019913A (zh) 2020-06-01
CA3104757A1 (en) 2020-01-02
EP3816163A1 (en) 2021-05-05
AU2019296091A1 (en) 2021-01-21
WO2020001420A1 (zh) 2020-01-02
EP3816163A4 (en) 2022-04-13
JP2022511213A (ja) 2022-01-31
KR20210024574A (ko) 2021-03-05
IL279637A (en) 2021-03-01
US20210292340A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
CN112543755A (zh) 一类细胞坏死抑制剂及其制备方法和用途
CN108283000B (zh) γ-羟基丁酸的前药及其组合物和用途
CN110036007B (zh) 吡啶化合物
JP6896113B2 (ja) ジアザ二環式置換イミダゾピリミジンおよび呼吸障害を治療するためのその使用
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
CN110642874B (zh) 一类细胞坏死抑制剂及其制备方法和用途
WO2021027911A1 (zh) 新型螺环类K-Ras G12C抑制剂
WO2020011246A1 (zh) 含苯环的化合物、其制备方法及应用
KR20070026414A (ko) Ｈｉｖ 인테그라제 억제제
WO2014134774A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN109843869B (zh) 1-[(吡啶-3-基-磺酰基)-1h-吡咯-3-基]甲胺衍生物及其药物组合物和用途
CN111018891B (zh) 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
KR20140014399A (ko) 사람 면역결핍 바이러스 복제 억제제
CN113683614A (zh) 用于治疗正粘病毒感染的稠合三环哒嗪酮化合物
CN111393415A (zh) 一种杂芳腈类化合物及其应用
CN113754654A (zh) 咪唑并吡啶类化合物及其用途
CN108689937B (zh) 吲唑类化合物及其在制备ido抑制剂类药物上的用途
CN108602807B (zh) 杂环磺酰胺衍生物及含有其的药物
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
EP3197452B1 (en) Inhibitors of hif prolyl hydroxylase
KR20220066290A (ko) Perk 억제 피롤로피리미딘 화합물
CN117321042A (zh) 用于治疗炎症性疾病或癌症的氧代二氢吲哚化合物
JP2023535692A (ja) 腸内分解性共薬、その調製及び使用
TW202144358A (zh) 用作ret激酶抑制劑的化合物及其應用
RU2793918C2 (ru) Ингибитор некроза клеток, способ его получения и применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050245

Country of ref document: HK